Incyte Corporation (incy)
INCY Earnings
Public earnings and growth snapshot for Incyte Corporation. Full earnings calendars, surprises, and multi-year history are available in Vest Terminal.
| Earnings growth (YoY) | 37.7% |
| Revenue growth (YoY) | 37.7% |
| Trailing P/E | 16.17 |
| Forward P/E | 14.03 |
| Last price | $124.64 |
| Market cap | $25.26B |
Start Free — open INCY in Vest Terminal
Access live data, filings, ownership, and analysis for Incyte Corporation.
Incyte Corporation FAQ
What does Incyte Corporation (INCY) do?
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refrac…
What is INCY's P/E ratio?
Incyte Corporation has a trailing P/E of 16.17× based on publicly available market data.
Does INCY pay a dividend?
Indicated dividend yield: none reported. Confirm ex-dates and payout history in Vest Terminal.
What sector is INCY in?
Incyte Corporation is classified in Healthcare (Biotechnology) on NMS.
What is INCY's market capitalization?
Approximate market cap: $25.26B.
What are the main risks for INCY?
Standard market, competitive, and execution risks apply; see the Risks section.
What are the strengths of INCY?
Potential positives include revenue growth of 37.7% year-over-year, earnings growth of 37.7% year-over-year.
Where can I get analyst estimates for INCY?
Public analyst price targets and consensus for Incyte Corporation are on the free /stocks/incy/estimates page. Deeper estimate history and models are available in Vest Terminal.